Table 1.
Completed clinical studies using 211At. (NTC number) is the ClinicalTrials.gov identifier.
| Institution, Reference | Clinical situation | Nb. Pts. | Study Objective | TAT-agent | Target | Adminis-tration | Act-ivity | Toxicity/effect |
|---|---|---|---|---|---|---|---|---|
| Duke University Medical Center, Durham, USA (9) (NCT00003461) | Recurrent surgically resected glioblastoma | 18 | Feasibility and safety | 211At-ch81C6 | tenascin | Surgically created resection cavity | 71–347 MBq | MTD, Not reached |
| Sahlgrenska University Hospital, Gothenburg, Sweden (8, 10–12) (NCT04461457) | Relapsed ovarian cancer | 12 | Safety, Toxicity Pharmacokinetics | 211At-MX35 F(ab')2 | NaPi2b | Intra peritoneal | 34–355 MBq | MTD, Not reached |
| Carl Gustav Carus University Hospital, Dresden, East Germany (7) | Recurrent carcinoma of the tongue | 1 | Palliation | 211At-labeled human serum albumin microspheres (15–25μm) | Tumor vasculature | Intra arterially (left lingual artery) | 200 MBq | Tumor necrosis/ tongue necrosis |
| University of California Berkeley and San Francisco, USA (2) | Thyroid gland disorders | 8 | Tracer study | 211At | Na+/I− symporter (NIS) | Per oral in 25ml water | 1.85 MBq | Thyroid uptake was established |